

# Development of hit and lead asymmetric anti-CD20xCD55 bispecific antibodies containing Fc variants with maximized serum half-lives and effector functions for cancer therapy

Korea University



ONCOLOGY	Hit
Product Type	Immunoglobulin Product(Bispecific antibody)
Indication	Non-Hodgkin lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Target	CD20 and CD55
MoA(Mechanism of Action)	Simultaneous binding to CD55 and CD20 → Enhanced complement-dependent cytotoxicity (CDC) → Efficient clearance of rituximab resistant tumor cells
Competitiveness	<p>First In Class</p> <ul style="list-style-type: none"> <li>• Unique mechanism of action of the anti-CD20xCD55 bispecific antibody.</li> <li>• Enhanced serum half-life and effector function through introducing an extending Fc-KU variant.</li> <li>• A bispecific antibody format that can be produced by simple bioprocessing steps.</li> </ul>
Development Stage	Hit
Route of Administration	Parenteral-Intravenous